Yahoo Finance Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know
Moderna (MRNA) closed at $339.57 in the latest trading session, marking a +1.97% move from the prior day. This move outpaced the S&P 500's daily gain of 0.3%.
Coming into today, shares of the biotechnology company had lost 24.44% in the past month. In that same time, the Medical sector lost 1.9%, while the S&P 500 gained 4.28%.
MRNA will be looking to display strength as it nears its next earnings release, which is expected to be November 4, 2021. The company is expected to report EPS of $9.01, up 1627.12% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.09 billion, up 3757.76% from the year-ago period.
MRNA's full-year Zacks Consensus Estimates are calling for earnings of $29.13 per share and revenue of $20.05 billion. These results would represent year-over-year changes of +1586.22% and +2395.05%, respectively.
Any recent changes to analyst estimates for MRNA should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.13% lower. MRNA is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note MRNA's current valuation metrics, including its Forward P/E ratio of 11.43. This valuation marks a discount compared to its industry's average Forward P/E of 25.01.
Investors should also note that MRNA has a PEG ratio of 0.39 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.54 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 175, putting it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
To read this article on Zacks.com click here.
